Meeting
2020 ASCO Virtual Scientific Program
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
Presenter
Sherene Loi, MD, PhD
Peter MacCallum Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04109066
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS604)
DOI
10.1200/JCO.2020.38.15_suppl.TPS604
Abstract #
TPS604
Poster Bd #
96
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).
Speaker: Miguel Martin, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
Speaker: Jonathan Spicer, MD, PhD, FRCPC
Videos & Slides
2024 ASCO Annual Meeting
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).
Speaker: Hui Liu
Videos & Slides
2024 ASCO Annual Meeting
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.
Speaker: Grace Mei Yee Choong, MD